Cargando…
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
BACKGROUND AND AIMS: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real‐world analysis to date, the effectiveness of pangenotypic, panfibrotic, single‐tablet, sofosbuvir/velpatasvir (S...
Autores principales: | Mangia, Alessandra, Milligan, Scott, Khalili, Mandana, Fagiuoli, Stefano, Shafran, Stephen D., Carrat, Fabrice, Ouzan, Denis, Papatheodoridis, George, Ramji, Alnoor, Borgia, Sergio M., Wedemeyer, Heiner, Losappio, Ruggero, Pérez‐Hernandez, Francisco, Wick, Nicole, Brown, Robert S., Lampertico, Pietro, Doucette, Karen, Ntalla, Ioanna, Ramroth, Heribert, Mertens, Michael, Vanstraelen, Kim, Turnes, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496473/ https://www.ncbi.nlm.nih.gov/pubmed/32449966 http://dx.doi.org/10.1111/liv.14537 |
Ejemplares similares
-
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders
por: Wedemeyer, Heiner, et al.
Publicado: (2022) -
Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019) -
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019) -
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019) -
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)